Dr Reddy's CEO On Clogged Semaglutide Pipeline
Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in...
By Bloomberg Markets · Bloomberg Markets
Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share. (Source: Bloomberg)